Means Investment CO. Inc. Has $1.21 Million Stake in Hims & Hers Health, Inc. (NYSE:HIMS)

Means Investment CO. Inc. increased its position in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 23.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 50,040 shares of the company's stock after purchasing an additional 9,508 shares during the period. Means Investment CO. Inc.'s holdings in Hims & Hers Health were worth $1,210,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. The Manufacturers Life Insurance Company boosted its position in Hims & Hers Health by 44.9% during the second quarter. The Manufacturers Life Insurance Company now owns 116,477 shares of the company's stock valued at $2,352,000 after purchasing an additional 36,081 shares during the last quarter. Creative Planning acquired a new position in Hims & Hers Health in the second quarter worth approximately $443,000. Sanctuary Advisors LLC bought a new position in Hims & Hers Health during the second quarter valued at approximately $415,000. Diversified Trust Co acquired a new stake in Hims & Hers Health in the third quarter valued at approximately $233,000. Finally, Strategic Wealth Partners Ltd. increased its stake in shares of Hims & Hers Health by 57.6% during the 3rd quarter. Strategic Wealth Partners Ltd. now owns 109,199 shares of the company's stock worth $2,011,000 after purchasing an additional 39,896 shares during the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Soleil Boughton sold 268,932 shares of the firm's stock in a transaction on Monday, January 6th. The shares were sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the sale, the insider now directly owns 169,803 shares in the company, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Anja Manuel bought 4,000 shares of the stock in a transaction on Tuesday, November 12th. The shares were purchased at an average price of $26.94 per share, with a total value of $107,760.00. Following the acquisition, the director now owns 4,000 shares in the company, valued at approximately $107,760. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. Over the last ninety days, insiders sold 1,167,913 shares of company stock worth $34,303,787. 17.71% of the stock is owned by corporate insiders.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS traded up $0.27 during midday trading on Wednesday, reaching $42.12. 17,307,987 shares of the company traded hands, compared to its average volume of 11,378,140. The firm has a market cap of $9.20 billion, a PE ratio of 95.72 and a beta of 1.35. The stock's 50-day simple moving average is $29.58 and its 200-day simple moving average is $22.86. Hims & Hers Health, Inc. has a 12 month low of $8.58 and a 12 month high of $44.43.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share for the quarter, beating analysts' consensus estimates of $0.06 by $0.26. The firm had revenue of $401.56 million during the quarter, compared to analysts' expectations of $382.20 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. The business's revenue was up 77.1% on a year-over-year basis. During the same period last year, the firm posted ($0.04) EPS. On average, equities research analysts expect that Hims & Hers Health, Inc. will post 0.29 EPS for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. BTIG Research initiated coverage on shares of Hims & Hers Health in a report on Tuesday, January 7th. They issued a "buy" rating and a $35.00 price objective for the company. TD Cowen reissued a "buy" rating and set a $28.00 price objective on shares of Hims & Hers Health in a report on Wednesday, November 20th. Piper Sandler upped their target price on Hims & Hers Health from $21.00 to $24.00 and gave the stock a "neutral" rating in a research report on Monday, January 6th. Citigroup lowered shares of Hims & Hers Health from a "neutral" rating to a "sell" rating and lifted their price target for the company from $24.00 to $25.00 in a research report on Friday, January 10th. Finally, Canaccord Genuity Group upped their price objective on shares of Hims & Hers Health from $28.00 to $38.00 and gave the stock a "buy" rating in a report on Monday, December 2nd. Two equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and an average target price of $25.13.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.